-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on Roivant Sciences, Raises Price Target to $56

Benzinga·10/28/2026 20:17:49
語音播報
Citigroup analyst Samantha Semenkow maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $46 to $56.